Why remdesivir might be a good bet against Covid-19

accreditation

New research sheds light on why the experimental drug remdesivir might become the most powerful weapon in the fight against Covid-19: It is highly effective against an enzyme that plays a crucial role in the spread of the new coronavirus.

Remdesivir is one of several drugs being fast-tracked in various coronavirus treatment trials around the world. Just last week, a small, "compassionate use" trial published in the New England Journal of Medicine found the drug improved outcomes for people with Covid-19.

More than two-thirds of 53 severely ill patients showed improvement in oxygen support, the Cedars-Sinai Medical Center researchers said. Seventeen of 30 patients who were on ventilators were able to be taken off the life-support machines, the study showed.

The latest research, published in the Journal of Biological Chemistry, explains how remdesivir, developed in 2014 to fight the Ebola epidemic, works against the new coronavirus.

'Direct-acting antiviral'

Remdesivir "is a very potent inhibitor for coronavirus polymerases", and if "you target the polymerase, the virus cannot spread, so it's a very logical target for treatment", explained study author Matthias Götte, chair of medical microbiology and immunology at the University of Alberta, in Canada.

Remdesivir tricks the coronavirus by mimicking its building blocks, the investigators found.

"These coronavirus polymerases are sloppy, and they get fooled, so the inhibitor gets incorporated many times and the virus can no longer replicate," Götte explained.

Evidence from this study and previous research in animals and cell cultures showed that remdesivir can be classified as a "direct-acting antiviral" against the new coronavirus, Götte noted.

This reinforces the promise of clinical trials being conducted worldwide of remdesivir in people with Covid-19.

Almost identical results

While the evidence provided by lab studies justify clinical trials, those results can't predict how remdesivir will work in human patients, Götte noted.

"We've got to be patient and wait for the results of the randomised clinical trials," he said in a university news release.

In February, Götte's lab published a study showing how remdesivir worked against the Middle East respiratory syndrome (MERS) virus, which is related to the new coronavirus that causes Covid-19, officially called SARS-CoV-2.

"We were optimistic that we would see the same results against the SARS-CoV-2 virus," Götte said. "We obtained almost identical results as we reported previously with MERS, so we see that remdesivir is a very potent inhibitor for coronavirus polymerases."

READ | Coronavirus | The chloroquine debate: Two experts weigh in

READ | Trials begin for potential Covid-19 drug - it was initially developed to treat Ebola

READ | How one patient's battle with Covid-19 changed US testing protocols

Image credit: Getty Images
We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
Zama zama crackdown: What are your thoughts on West Village residents taking the law into their own hands?
Please select an option Oops! Something went wrong, please try again later.
Results
Authorities should bring in the army already
11% - 2140 votes
Illegal miners can't be scapegoated for all crime
49% - 9853 votes
What else did we expect without no proper policing
36% - 7268 votes
Vigilante groups are also part of the problem
4% - 731 votes
Vote
Rand - Dollar
16.43
-0.2%
Rand - Pound
19.86
-0.1%
Rand - Euro
16.70
-0.2%
Rand - Aus dollar
11.50
+0.2%
Rand - Yen
0.12
-0.0%
Gold
1,777.03
+0.1%
Silver
20.17
+0.1%
Palladium
2,163.00
+0.1%
Platinum
938.50
+0.1%
Brent Crude
92.34
-3.0%
Top 40
64,503
-0.3%
All Share
71,370
-0.2%
Resource 10
64,524
-1.3%
Industrial 25
87,172
+0.1%
Financial 15
16,287
+0.3%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE